Greenphire, the leading provider of payment technologies for the clinical trials industry, today announce the launch of a strategic partnership with Ernst & Young.
Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced the launch of a strategic partnership with Ernst & Young. The partnership will combine Greenphire’s industry leading eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young’s advisory practice for clients in the pharmaceutical industries.
Within the scope of the partnership, Greenphire’s clients will have access to specialists within Ernst & Young’s global consulting and advisory practice that focuses on global HCP transparency regulatory compliance (e.g. – The US Sunshine Act). This relationship will increase the strength of Greenphire’s eClinicalGPS technology by giving clients the ability to leverage Ernst & Young’s market leading advisory practice in concert with Greenphire’s market leading payment and data aggregation technology. Ernst & Young’s advisory practice will further assist Greenphire’s clients to comply with 75+ transparency regulations globally.
Additionally, Ernst & Young’s extensive proprietary research will be routed into a new Greenphire technology solution. The technology, currently in development, will be a first-of-its-kind, web-based SaaS solution to manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all aspects of pharmaceutical operations.
Sam Whitaker, co-founder and CEO of Greenphire, comments: "We are delighted to work with Ernst & Young in what is sure to be an industry-changing partnership. Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant. We are very excited to be able to offer them access to an incredible resource such as Ernst & Young.”
Martin Holyoake, Partner at Ernst & Young said: “We are proud to be working with Greenphire to help ensure that clients successfully navigate the complicated legislative landscape and deliver value. The deep technical knowledge and grounded relationships formed as a result of our long standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight. We look forward to working with Greenphire to bring tangible benefits to our clients.”
For further information on Greenphire and its innovative solutions please email: [email protected], call +1 215-609-4640 or visit www.greenphire.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.